N-Nitroso Abemaciclib Impurity 1: Analytical Significance and Role in Pharmaceutical Testing
In pharmaceutical development, impurity control is rarely limited to identifying the compounds formed during synthesis. Modern analytical programs also have to consider trace-level impurities that may arise from the chemistry of the active pharmaceutical ingredient, manufacturing conditions, raw materials, and degradation pathways. Nitrosamine impurities have become an important part of this assessment because some nitrosamines have demonstrated mutagenic and carcinogenic potential.
Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor used in the treatment of certain types of breast cancer. Its chemical and analytical profile makes impurity characterization an important part of pharmaceutical quality control. Among the impurity categories associated with abemaciclib are N-nitroso-related compounds, including N-Nitroso Abemaciclib Impurity 1.
A dedicated reference standard for this impurity can help analytical laboratories establish identity, investigate trace-level signals, and support method development and validation activities.
What Is N-Nitroso Abemaciclib Impurity 1?
N-Nitroso Abemaciclib Impurity 1 is a nitrosamine-related impurity associated with the abemaciclib molecule. Chemicea lists the compound under its abemaciclib nitrosamine reference-standard portfolio as CAT. No. CP-A97001, with the molecular formula C27H31F2N9O and molecular weight 535.60 g/mol. A CAS number is not assigned on the current Chemicea product listing.
The compound is analytically significant because the presence of a nitroso functionality changes the toxicological and regulatory considerations surrounding an impurity. Consequently, laboratories investigating potential N-nitroso species need suitably characterized reference materials rather than relying solely on retention time or theoretical mass.
The N-Nitroso Abemaciclib Impurity 1 reference standard is intended for analytical applications and can be used as a comparator during impurity investigations.
Why Nitrosamine Impurities Receive Special Attention
Nitrosamines are not simply another category of routine process impurities. Their potential genotoxicity has resulted in increased regulatory attention and more extensive risk assessments throughout pharmaceutical manufacturing.
A nitrosamine may originate from interactions between an amine-containing substrate or intermediate and a source of nitrosating species. The exact risk depends on the molecular structure, reaction environment, manufacturing process, exposure level, and toxicological characteristics of the individual compound.
This is particularly relevant when pharmaceutical molecules contain structural features that can participate in nitrosation chemistry. The assessment therefore begins with understanding the molecular structure and manufacturing process rather than assuming that every possible nitrosamine will necessarily form.
For analytical scientists, the practical challenge is different: once a potential impurity has been identified, it must be distinguished from the parent API and from other structurally related compounds.
Abemaciclib as the Parent Drug
Abemaciclib has the molecular formula C27H32F2N8 and a molecular weight of approximately 506.61 g/mol according to Chemicea's reference-standard listing. It is a small-molecule CDK4/6 inhibitor and is marketed as Verzenio in the United States.
The FDA-approved prescribing information indicates that hepatic metabolism is the principal route of abemaciclib clearance. CYP3A4 is primarily involved in its metabolism, with N-desethylabemaciclib (M2) identified as the major metabolic pathway. Other reported metabolites include M20, M18, and M1.
This distinction is important when developing an analytical method. A laboratory may encounter several chemically related species during analysis, and not all of them should be classified as nitrosamine impurities. Metabolites, process-related impurities, degradation products, and nitrosamine-related species can have substantially different origins.
Where N-Nitroso Abemaciclib Impurity 1 Fits Into Impurity Profiling
A comprehensive impurity profile for an abemaciclib drug substance or drug product can involve several different categories:
Process-related impurities
Starting-material or intermediate-related impurities
Degradation products
Metabolites
Oxidative impurities
N-nitroso impurities
Other potentially genotoxic impurities
Chemicea's abemaciclib portfolio includes several of these categories, including N-nitroso abemaciclib impurities, N-oxide impurities, process impurities, and metabolites. This illustrates why analytical laboratories need more than a single impurity standard when investigating the overall impurity profile of a pharmaceutical compound.
N-Nitroso Abemaciclib Impurity 1 should therefore be viewed as one component of a broader analytical strategy rather than as a replacement for conventional abemaciclib impurity testing.
The Importance of a Dedicated Reference Standard
Trace-level impurity analysis is highly dependent on reliable identification. A chromatographic peak by itself does not always establish the identity of an unknown compound.
A dedicated reference standard provides a physical material against which an analytical signal can be compared. Depending on the analytical procedure, laboratories may evaluate parameters such as:
Chromatographic retention time
Mass-to-charge ratio
Fragmentation pattern
UV response
Relative retention behavior
Peak purity
Response characteristics
Quantitative assay response
For LC-MS or LC-MS/MS workflows, comparison with an authentic reference material can be particularly useful when confirming that a detected signal corresponds to the expected molecular species.
The reference standard can also help laboratories distinguish a suspected nitrosamine from structurally related abemaciclib impurities that may generate similar chromatographic or mass-spectral responses.
Analytical Method Development for Nitrosamine Monitoring
Method development for nitrosamine impurities generally requires greater sensitivity than routine assay testing because these compounds may need to be detected at very low concentrations.
Liquid chromatography coupled with mass spectrometry is commonly considered when highly sensitive and selective detection is required. The final analytical technique, however, should be selected according to the specific compound, matrix, required detection capability, and laboratory method-validation strategy.
During development, analysts may investigate:
Chromatographic separation
The impurity must be adequately separated from abemaciclib and other closely related compounds.
Detection sensitivity
The method should provide sufficient sensitivity for the laboratory's intended reporting or control threshold.
Specificity
Interference from the API, excipients, solvents, degradation products, and other impurities needs to be evaluated.
Linearity and range
The response should be assessed across an appropriate concentration range.
Precision and accuracy
Reproducibility and recovery should be established according to the purpose of the method.
Limit of detection and limit of quantification
These parameters are particularly relevant for trace-level impurity investigations.
Solution and sample stability
The stability of standards and prepared samples should be considered to avoid analytical artifacts.
A reference standard such as N-Nitroso Abemaciclib Impurity 1 can be incorporated into these studies to establish the analytical response of the target impurity.
Reference Standards and Regulatory Documentation
Regulatory assessment of impurities depends not only on whether an impurity is detected, but also on whether the analytical procedure used to detect and quantify it is appropriately established.
The European Medicines Agency's public assessment report for abemaciclib notes that an identified genotoxic impurity was subject to an appropriate specification and that the analytical methods used were described and validated in accordance with applicable ICH principles. The report also discusses the use of reference standards for identity, assay, and impurity testing.
This highlights an important point: reference standards are part of the analytical evidence supporting impurity control. They help connect an analytical result with a defined chemical entity.
For laboratories working on pharmaceutical development, having access to an appropriate standard can therefore simplify method-development studies and improve confidence when investigating trace-level peaks.
N-Nitroso Abemaciclib Impurity 1 in Quality Control Work
Once an analytical method has been established, a reference standard may have several practical uses within a pharmaceutical quality-control environment.
It can support:
Method development:
The standard can be used during initial chromatographic and mass-spectrometric investigations to establish suitable detection conditions.
Method validation:
Analysts can evaluate specificity, accuracy, precision, linearity, and sensitivity using a known amount of the impurity.
Routine impurity monitoring:
Where the impurity is included within the laboratory's established control strategy, the reference material can assist with identification and quantification.
Investigations:
If an unexpected chromatographic peak appears during stability testing or process investigations, comparison with a reference standard can help determine whether the signal corresponds to the suspected nitrosamine.
Reference material qualification:
The material can contribute to laboratory procedures for characterization and analytical comparison.
These applications make the quality and documentation associated with the reference material important considerations when selecting a supplier.
What Analysts Should Consider When Selecting the Standard
Not every material described as an impurity standard is necessarily suitable for every analytical purpose. Laboratories should review the available documentation and qualification information before incorporating a standard into a regulated workflow.
Important considerations can include:
Correct chemical identity
Assigned product or catalogue number
Molecular formula and molecular weight
Purity or characterization information
Certificate of Analysis
Storage requirements
Recommended handling conditions
Lot information
Availability of supporting analytical data
Suitability for the intended analytical application
For trace-level nitrosamine work, documentation becomes particularly important because the concentration being measured may be extremely low compared with the amount of parent API present in the sample.
Chemicea's N-Nitroso Abemaciclib Reference Standard
Chemicea Pharmaceuticals maintains a dedicated portfolio of abemaciclib-related reference standards covering several impurity classes. Its current listing identifies N-Nitroso Abemaciclib Impurity 1 as CP-A97001, with a molecular formula of C27H31F2N9O and molecular weight of 535.60 g/mol. The listed availability status is “Please Enquire.”
Chemicea also lists other N-nitroso abemaciclib-related materials, including N-Nitroso Abemaciclib Impurity 2, N-Nitroso Abemaciclib Impurity 3, N-Nitroso Abemaciclib Metabolites M2, and N-Nitroso Abemaciclib N-Oxide Impurity.
This broader range can be useful for laboratories that need to investigate more than one potential nitrosamine-related species during analytical development.
Why Chemical Characterization Matters
One of the most challenging aspects of impurity analysis is that structurally similar compounds can behave similarly under certain analytical conditions. A small structural modification may alter chromatographic retention, ionization efficiency, fragmentation behavior, and detector response.
For this reason, analysts should avoid identifying an impurity based solely on an assumed retention time or a single mass signal whenever definitive confirmation is required.
Orthogonal information can provide stronger evidence. Depending on the analytical objective, laboratories may combine chromatographic separation with high-resolution mass spectrometry, MS/MS fragmentation, spectroscopic information, or comparison against an authentic reference material.
The use of a well-characterized reference standard gives the laboratory an experimental benchmark rather than relying entirely on predicted analytical behavior.
A Practical Role in Pharmaceutical Development
The importance of N-Nitroso Abemaciclib Impurity 1 extends beyond one individual test. It fits into a larger workflow involving impurity assessment, analytical method development, quality control, process understanding, and regulatory documentation.
For manufacturers and analytical laboratories working with abemaciclib, the objective is not simply to detect an impurity. The objective is to understand what the impurity is, determine whether it is present, measure it accurately when required, and maintain an appropriate level of control based on the applicable scientific and regulatory framework.
That process begins with reliable analytical information.
Conclusion
N-Nitroso Abemaciclib Impurity 1 is a specialized nitrosamine-related reference material associated with the analytical characterization of abemaciclib. Chemicea identifies the compound as CP-A97001, with the molecular formula C27H31F2N9O and molecular weight 535.60 g/mol.
For pharmaceutical laboratories, its primary value lies in providing a defined analytical reference for method development, impurity identification, validation studies, and investigations involving potential nitrosamine species.
As pharmaceutical impurity control continues to become more sophisticated, laboratories increasingly need reference materials that correspond to specific and chemically relevant impurities. A dedicated N-Nitroso Abemaciclib Impurity 1 standard can therefore serve as an important analytical tool when developing a robust strategy for monitoring abemaciclib-related nitrosamine impurities.
Comments